drug
triheptanoin
Marketedupdated 3mo agoby $RARE Ultragenyx Pharmaceutical Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying triheptanoin
- phase3A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD
- phase2Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
- phase2Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
- —Expanded Access to Triheptanoin
- phase1Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency
- phase2A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease
- phase2The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 30, 2027
322 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (2)
- Nov 14, 2034formulationUS 12551461
- Apr 28, 2029formulationUS 86977482.7y
FDA exclusivities (1)
- Jun 30, 2027ODE-311Orphan Drug (7y)322d
News(1)
- Biotechs bring big launches and pharma rivalries into Q2 earnings periodWith the second quarter earnings period underway, BioSpace examines five biotechs with meaningful catalysts that analysts and investors are watching.biospace · 13d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that